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Abstract
Background
Anti-RhD immunised donors provide anti-RhD immunoglobulins used for the prevention of
rhesus disease. These donors are periodically hyper-immunised (boostered) to retain a high
titer level of anti-RhD.
Study design and methods
We analysed anti-RhD donor records from 1998 to 2016, consisting of 30,116 anti-RhD
titers from 755 donors, encompassing 3,372 booster events. Various models were fit to
these data to allow describing the anti-RhD titers over time.
Results
A random effects model with a log-linear anti-RhD titer decline over time and a saturating
titer response to boostering is shown to fit the data well. This model contains two general
model parameters, relating timing and maximum of the booster effect, as well as two param-
eters characterizing the individual donor, namely how fast the booster effect saturates with
current titer and the anti-RhD decline rate. The average individual log2 decline is 0.55 per
year, i.e. a 32% decline in absolute titer, with half of the donors declining between 13% and
41% per year. Their anti-RhD titer peaks around 26 days following a booster event. Booster-
ing response reduces with higher titers at boostering; at median titer (log2 11) the mean
increase per booster is log2 0.38, that is from an absolute titer of 2048 to 2665 (+30%), with
half of all donors increasing between 16% and 65% in their titer.
Conclusion
The model describes anti-RhD titer change per individual with only four parameters, two of
which are donor specific. This information can be used to enhance the blood bank’s immuni-
sation programme, by deriving individualized immunization policies in which boostering is
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adjusted to the anticipated anti-RhD decline, effectiveness of boostering and titer levels
required.
Introduction
Anti-RhD immunised donors provide anti-RhD immunoglobulins, which is the main constit-
uent in the prophylaxis used for the prevention of foetal rhesus disease [1]. During pregnancy
or birth of an RhD-positive child, RhD-negative women may become immunized against
RhD. Their antibodies can cross the placenta, destroying the red blood cells of a (subsequent)
RhD-positive foetus, the cause of foetal rhesus disease. Timely administration of anti-RhD
immunoprophylaxis prevents such immunisation and thereby this disease [2].
Administration of anti-RhD immunoprophylaxis has been applied since 1969 in the Neth-
erlands. With added antenatal administration improving performance further since 1998, this
practice has lowered the number of intrauterine foetal deaths by a hundredfold [1].
The success of this practice however presents a difficulty to its own continuation: natural
immunisation has become rare, which has led to a decline in the availability of anti-RhD
donors [3]. To uphold the donor population in the Netherlands, woman over reproductive age
and man as well have been purposely immunized. As anti-RhD titers normally decline over
time without exposure, donors are also periodically hyper-immunised (boostered) in order to
stimulate continued production of anti-RhD immunoglobulins. Comparable to vaccination
however, such booster events are a notable burden on donors.
In this manuscript we describe an analysis of historical data of anti-RhD donors in the
Netherlands. Our aim was to quantify the effect of booster events, as dependent on known var-
iables. A model which allows prediction of the anti-RhD titer response in donors can be used
to rationalize and optimize boostering strategies for donors, minimizing the burden on donors
whilst maintaining anti-RhD production levels required.
Materials and methods
Description of the data-set
We analysed anti-RhD donor records of the Dutch blood-bank Sanquin from 1998 to 2016
[3]. Data on anti-RhD titers from donations were available from September 1994 onwards.
However, we noted a large number of substantial anti-RhD titer increases unexplained by rec-
ords of preceding booster events. As such observations indicating lower data validity occur
almost exclusively in the records before 1998, these earlier data were omitted from our
analyses.
Donors are allowed to donate every two weeks, and their anti-RhD titer is measured at each
donation on discrete log2 scale. Policy is for new donors to be boostered at their first three to
five donations to bring their anti-RhD titer up to a high level, and subsequently for boosters to
be administered when anti-RhD titer lowers. In total the analysed data-set comprises 30,116
anti-RhD titers from 755 repeat donors, encompassing 3,372 booster events (mean records per
donor 39.9, median 20 and maximum 277, mean booster events per donor 4.5, median 4 and
maximum 22). For 90% of only the records from 2005–2016 the precise donation date is
known. When the donation date was not recorded, as a proxy the date logged for the availabil-
ity of the anti-RhD test results was used. On average test results were available 2.6 days after a
donation.
All donors included in our study have provided consent for their donations and anon-
ymized data to be used for scientific research. A dataset with titers and boostering events is
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Analyses
Due to the complex nature of the data, which includes multiple booster responses as well as
natural titer change over time, we have performed our analysis in several steps, where the final
step (Step 3) fits a model on the full data-set. In smaller initial steps we first examined how
anti-RhD titer changes in the absence of boostering, Step 1, and next the effect of a single
booster event, Step 2. While in Step 2A we focus on the timing of the boostering effect, in Step
2B we focus on the magnitude of the induced anti-RhD titer increase. For Steps 1 and 2A we
used only the data with exact known donation dates, while for Steps 2B and 3 we used the full
data-set. The steps are explained in detail below. All analyses were performed in the R language
and environment for statistical computing (version 3.1.2) [4].
Step 1: Natural anti-RhD decline. We first fit anti-RhD titer change over time in the
absence of boostering. To eliminate the impact of boostering we considered only donations
100 days or more since any last booster event. Note that the 100 day period was derived
from the results obtained from Step 2A. Each first compliant titer measurement was set as
time 0, i.e. follow-up time restarted with an intervening booster event for a donor. The
dependent model variable was the change in anti-RhD titer from measurement at time 0,
the explanatory variable time. This data-subset comprised of 9,687 anti-RhD titer differ-
ences from 323 individuals. Using maximum likelihood assessment, the lowest BIC score
was obtained for a model with random effects and log-linear decline over time; i.e. Ti(t) −
Ti(t = 0) = Dit + 2. Here Ti(t) represents the log2 titer measurement at time t of donor i. By
Di  NormalðmD ¼ D;s2DÞ the natural log-linear rate of change for donor i is given, and the
measuring error is 2 Normalðm2 ¼ 0; s22Þ.
Step 2A: Timing of the boostering effect. Next we examined the effect of boostering, first
focussing on the time envelope of the boostering effect. The model was fit up to 200 days fol-
lowing boostering or until a next booster event. To isolate the individual boostering effect we
also excluded boosters less than 100 days from a previous booster event. The remaining data-
subset comprises of 3,137 changes in anti-RhD titer following 709 booster events of 250
donors. We fitted the boostering effect on top of the population average log-linear decline rate
D established in Step 1. Using nonlinear least squares regression, the lowest normalised
squared errors score was obtained with logistic saturating increase from the time of boostering:
the fit formula was Ti tð Þ   Ti t ¼ 0ð Þ ¼ 2B 11þe  Ht  
1
2
 
þ Dt. In this formula B is the maxi-
mum increase in anti-RhD titer from boostering, and H scales the speed of the increase after
boostering. The maximum anti-RhD titer difference was estimated at 26 days from boostering.
This number was used in the next step of the analysis.
Step 2B: Magnitude of the boostering effect. The magnitude of the boostering effect was
found to be strongly correlated with a donor’s anti-RhD titer at boostering. We fitted the
change in log2 titer at its peak value with log2 starting titer as the explanatory variable. Peak
value was defined as the measurement at the first time point per donor per booster event that
was from 26 to 50 days subsequent to boostering. We excluded donations with a previous
booster event occurring less than 50 days before the booster event of interest, but in this analy-
sis did not exclude subsequent boosters; this would have resulted in too little observations
especially in the low starting titer region, since new donors with low starting titer are boostered
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several times. In effect this analysis establishes a maximum in single boostering effect. The
data-set for this analysis contained 1,992 titer changes after boostering of 550 donors. Using
nonlinear least squares regression, a logistic decline in boostering effect was found to fit the
data well, i.e. Ti tð Þ   Ti t ¼ 0ð Þ ¼ 2B 1   11þe  LTiðt¼0Þ
 
þ tD, where B again represents the max-
imum boostering effect, and L scales the speed of the decline of the boostering effect.
Step 3: The integral model. Finally, putting together our findings from the previous
steps, we fitted a non-linear random effects model to the full dataset using maximum-likeli-
hood estimation. We assumed each individual booster event to have an independent effect on
anti-RhD titer. The integral model for change C in log2 titer can then be formulated as:
C tð Þ ¼ Ti tð Þ   Ti t ¼ 0ð Þ
¼ Dit þ
Pj¼mi
j¼1 ðxi;j> tÞ4B
1
1þ e  Hðt  xi;jÞ
 
1
2
 
1  
1
1þ e  LiTiðt¼xi;jÞ
 
þ 2
Here xi,j represents the jth boostering of donor i, who received mi boosters in total. We refitted
the earlier individualised constant log-linear decline rate Di in this random effects model.
Since timing of the boostering effect H has very little impact on the integral model fit (resulting
in flat likelihood surface), it was infeasible to re-fit this model parameter. The parameter value
was therefore taken from results of Step 2A. The magnitude of the boostering effect B was re-
fit, as was the logistic saturation in the effect Li, now as an individualised random effects
parameter.
The model was run initially using the titers at the time of boostering Ti(t = xi,j) as measured.
To have the model fully predictive, starting titers at the time of boostering were derived from
the model fit and the model parameters re-estimated. This process was iterated until the fitted
parameters reached steady state values (in the first seven digits) after 30 loops. In this proce-
dure titer estimates for Ti(t = xi,j) below 0 were rounded up to 0. Starting parameter values for
the optimisation procedure were based on results from Steps 1 and 2.
Model check and validation. The average absolute and squared residuals were calculated
per donor to check the model fit, with model titer predictions less than zero rounded up to 0.
We validated the model by refitting the model on the records of a random subset of 500 of the
755 donors (through Steps 1, 2A and 3). Next, using the resulting random effects distributional
constraints we refitted Di and Li for the 255 donors outside the main fit, by maximising the
likelihood:
Li ¼ LðDi;; LijD;s
2
D; L; s
2
L; sD;LÞ
Qk¼wi
k¼1 CiðtkjDi; LiÞLð2 js
2
2
Þ
Here Ci(tk) is the kth difference in measurements, and wi the total number of measurement dif-
ferences for donor i. Lð2 js2
2
Þ is the probability density function of the normal distribution,
and LðDi;; LijD;s2D; L; s
2
L; sD;LÞ is the probability density function of the bivariate normal dis-
tribution [5]. The optimum in likelihood per donor was determined by maximizing the nega-
tive of the log of Li. Again this fitting procedure is iterated, updating titers at boostering in
each fit from the previous fit (the initial fit using measurements, 50 iterations per donor).
Results
Step 1: Natural anti-RhD decline
The best fit to the data-set from which we excluded booster events was obtained with a ran-
dom-effects model, with a log-linear decline rate in anti-RhD titer (see Fig 1). In a random
effects model the random effects parameters are fit per individual, where the individual
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estimates combined are restrained to form a normal distribution surrounding a population
mean [6]. Those donors who decline slowly remain unboostered longer and will therefore pro-
vide a relatively large number of high titers at later time points. This would lead to biased esti-
mates of the overall decline rate in an analysis that would not group observations per
individual (see also S1 Fig). However, since the random effects model fits the data per individ-
ual, it is unaffected by this form of bias.
Step 2A: Timing of the boostering effect
Boostering usually leads to an increase in anti-RhD titer (see Fig 2). To analyse the timing of
this effect, we fitted a model to the average titer-change of all donors over time since booster-
ing. A peak in anti-RhD titer appears to be reached quickly, at around 26 days from boostering.
After 26 days the average anti-RhD titer declines again log-linearly, at the rate determined in
Step 1.
Step 2B: Magnitude of the boostering effect
From Fig 2 it also becomes clear that the increase in anti-RhD titer from boostering is corre-
lated with the donor’s titer at the time of boostering: the increase is substantially lower when
the starting titer is high. In Fig 3 the peak increase in titer, (assumed at 26 to 50 days from
boostering, see Step 2A), is plotted against the titer at the time of boostering. The best fit for
this relationship was found modelling the log anti-RhD titer increase as logistically saturating
Fig 1. Random effects model fit to the natural anti-RhD titer decline of donors in the absence of boostering. A jitter of
1.75 was applied to the titer change measurements to enhance interpretability of the data. For individual fits, the line ends at a
donor’s maximum time of measurement. Note that for 5% of donors a small positive annual change is modelled due to
measurement errors and since it is not possible to restrict the model to negative values.
https://doi.org/10.1371/journal.pone.0196382.g001
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with the log anti-RhD starting titer. Note that while on the log scale monotonic decrease in the
booster effect with starting titer is clear, translated to an absolute scale the magnitude of
increase seems to remain constant over a broad range of starting titers (shown in S2 Fig).
Step 3: The integral model
By combining the findings from the earlier steps, we obtain a model which describes the full
data-set. With the assumption that individual booster events affect anti-RhD titer indepen-
dently, our integral model of anti-RhD titer change in donors includes only four parameters.
Two of these were fit as donor level parameters, namely the natural decline rate, and the speed
of saturation in titer response with the starting titer at boostering. The two general model
parameters determine the maximum boostering effect (at a starting titer log2 0), and the time
to titer increase after boostering. Using their first anti-RhD titer measurement, the dates of
booster events and their two fitted individual parameters, the model allows predicting all fur-
ther titer measurements of a donor (see Fig 4).
The average donor experiences an annual decline in log2 anti-RhD titer of 0.55 (see
Table 1). This translates to a decline of 32% of a donor’s absolute titer every year. Of all donors
11% are fit with a (small) positive annual change, which is biologically implausible and likely
an artefact of the short follow-up time for some donors and the rather large error in
Fig 2. Change in anti-RhD titer after boostering. A jitter of 1.95 was applied to the titer change measurements to enhance
interpretability of the data. The rolling average is calculated per 100 data points; the data was sorted by days from boostering
but otherwise randomly ordered, per each consecutive 100 points both the average in titer change and the average in days
from boostering was calculated. The population average change in log2 titer is fit with a model of logistic increase on top of the
population average decline determined in Step 1. The upper and lower dotted lines show the model fit for all booster events
where the starting log2 anti-RhD titer was 11 and 11 respectively (log2 11 being the median starting titer). A peak in anti-
RhD titer is reached quickly, at around 26 days for all estimates. Note however the paucity of titer measurements following
early after boostering, as donations are at least 14 days apart. For a longer time scale and full data visualisation, see S1 Fig.
https://doi.org/10.1371/journal.pone.0196382.g002
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measurements; the model estimates that in one third of records the actual titer is at least log2
0.60 above or under the measured titer. To exclude the implausible values by these causes, we
restrict our model summary to the 50% limits of the fit donor distribution. We see that indi-
vidual donors vary greatly, with the mid half of donors estimated to decline from 0.20 to 0.77
log2 per year (-13% to -41% in absolute titer).
Starting at a population median titer of log2 11 the average donor’s increase in anti-RhD
titer due to boostering is log2 0.38 (+30% in absolute titer value). Starting from log2 3, 9 or 13
this increase is fit respectively as log2 4.26, 0.73 and 0.20 (+1816%, +66% and +15% on absolute
scale). Relative variation between donors is especially large at high titer; from titer at booster-
ing of log2 13 the lower 25
th percentile of donor’s goes up at most log2 0.10 per booster event,
while the top 25th percentile is still expected to go up log2 0.42 or more (7% and 34% absolute
increase respectively).
With the fitted model we can analyse the anticipated effect of different boostering regimes.
If boostering would occur at a fixed interval, a donors’ titer is expected to reach a dynamic pla-
teau where the increase in titer by boostering equals the decline in titer over the interval.
When boostered annually the average donor’s titer is expected to fluctuate between log2 9.90
just before boostering and 10.40 at 26 days after boostering. Average titer over the year
between booster events would be log2 10.16.
Fig 3. Peak in anti-RhD titer gain after boostering. A jitter of 1.95 was applied on the measurements of both titer change
and titer at boostering to enhance interpretability of the data. Individuals were not boostered in the 50 days preceding the
booster of interest. Black circles denote the approximate peak in increase assumed at 26–50 days from boostering (see Step 2A
results), when a donor was boostered only once. Blue crosses denote this increase when one or more boosters were given
subsequent to the booster of interest. Our best model fit to all these data-points together (shown for t = 26) hence represents
an overestimate of the titer gain from boostering once. Also shown is the fit dependence from our final model (see Step 3 in
the main text, shown for an average individual and also for 26 days from boostering).
https://doi.org/10.1371/journal.pone.0196382.g003
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The average donor’s plateau titer would decrease to log2 8.28 when boostering would occur
only once per two years. As boostering has more effect at lower starting titers, increasing the
boostering frequency has less effect on the plateau log2 titer: it increases to 11.31 at a booster-
ing frequency of thrice per two years. The relative gain in titer with boostering is greater for
those most sensitive to boostering: for those at the highest 25th percentile, changing frequency
from 0.5 to 1.5 times per year increases the plateau log2 titer from 12.18 to 16.04.
76 of the 755 donors (10%) in our data-set are male, their median estimated yearly decline
was log2 0.36 versus log2 0.42 for the females. Starting at log2 11, median increase from boos-
tering was 0.50 for men versus 0.41 for women. Neither gender difference was statistically sig-
nificant; t-test p = 0.61 and p = 0.48 respectively testing for difference in the mean of the
parameters Di and Li by gender.
We did find a significant correlation between age at first donation of a donor and the fitted
decline rate Di, at −0.119 (Pearson’s correlation, p = 0.00) (see S3 Fig).We found no indication
for influence of age on the boostering effect; the correlation between age at first recorded
booster event and Li was +0.009 (p = 0.827).
Fig 4. Four examples of model fits to individual donor titers observed over time. (See S5 Fig for the model fits for all individual
donors).
https://doi.org/10.1371/journal.pone.0196382.g004
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Model check and validation
On average, the absolute error in prediction per measurement is log2 0.63 (the mean squared
error is log2 0.75). For 94 of the 755 donors (12%) the mean absolute error is more than log2 1,
for 16 donors (2%) this error is more than log2 2 (see S2 which contains graphs for the individ-
ual model fits for all donors, ordered by their mean absolute error). Among those with larger
fit errors we see 7 donors who despite being boostered–some up to 4 or even 5 times–never
reached a titer higher than log2 5; they seem unresponsive to boostering (see S5 Fig for donors
724, 729, 735, 747, 752, 753 and 755).
When refitting the model over the records of a random subset of 500 of all 755 donors,
model parameters changed only slightly (see S4 Fig). For the donor records included in the
refit of the model the average absolute model fit error was 0.63, which is identical to the mean
error in the main fit over all donors. The mean average error is only slightly higher (0.65) for
the records of the remaining 255 donors. Their measurements were approximated by the
model fitting only parameters Di and Li, as restrained by the refit random-effects model (see
Methods).
Discussion
The presented model is a simplification of biological reality. The processes underlying the
dynamics of anti-RhD titer change are actually complex, involving many immune cell types
[7]. Yet, our model does capture what is most important: the fact that titers in donors gradually
decline over time unless boostered, that the impact of boostering saturates with increasing
titer, and that of these effects the magnitudes are personal. This allows our model to describe
how anti-RhD titer changes over time in individual donors.
When a donor is boostered a higher initial titer results in lower immune response on log
scale. Although the absolute response in anti-RhD production may, as long as it is not too
high, be independent of the starting titer, clearly most if not all anti-RhD production is sup-
pressed above some individual maximum titer level. We can only speculate as to this apparent
Table 1. Model fit.
Parameter fit Annual log2
change in
anti-RhD
titer
Boostering effect
in log2 titer at
starting titer log2
3
Boostering effect
in log2 titer at
starting titer log2
9
Boostering effect
in log2 titer at
starting titer log2
11
Boostering effect
in log2 titer at
starting titer log2
13
Mean eventual
log2 titer when
boostering 0.5
times yearly
Mean eventual
log2 titer when
boostering once
yearly
Mean eventual
log2 titer when
boostering 1.5
times yearly
Population
averagea
- 0.55 + 4.26 + 0.73 + 0.38 + 0.20 8.28 10.16 11.31
Upper 25th
percentile of
fit donorsb
- 0.20 + 4.84 + 1.21 + 0.72 + 0.42 12.18 14.64 16.04
Median value
of the fit
donorsb
- 0.42 + 4.33 + 0.78 + 0.41 + 0.22 9.47 11.53 12.75
Lower 25th
percentile of
fit donorsb
- 0.77 + 3.76 + 0.45 + 0.21 + 0.10 7.37 9.09 10.11
a Population average values directly from the model fit.
b As a fraction of the population of anti-RhD donors that were fit with the model (first column N = 755 donors, remaining columns N = 590, excluding 165 donors who
were never boostered).
While the maximum recorded titer measurement is log2 18, only 2% of all measurements were equal or greater than log2 14, the median measurement was log2 11.
https://doi.org/10.1371/journal.pone.0196382.t001
Predicting anti-RhD titers in donors
PLOS ONE | https://doi.org/10.1371/journal.pone.0196382 April 26, 2018 9 / 13
antibody-mediated immunosuppression; understanding the phenomenon mechanistically
would require further empirical research.
It has long been known that individuals differ substantially in the maximum of their anti-
RhD titer: famously, one man in Australia with an exceptionally high titer was solely responsi-
ble for a considerable fraction of all immunoprophylaxis produced within this country [8]. Yet
proper quantification of such individual differences is needed to allow optimisation of the
anti-RhD yield whilst minimizing donor exposure to RhD-positive blood.
The titer response data analysed is unique in extent: we know of no other published infor-
mation on anti-RhD titer response over such long follow-up time. Only the availability of mea-
surements on such a large number of donors exposed to multiple booster events allowed
modelling of individual responses. Yet limitations of our results are due to the observational
and historical nature of the data.
For instance, unfortunately it was not recorded which donors were newly immunised and
which immunised naturally by pregnancy with an RhD-positive foetus. Therefore we could
not address whether processes may be different between natural versus induced immunisation,
and when first becoming immunised compared to when hyper-immunised. Unless infertile,
woman under 45 did not receive any boosters, recruitment differed between sexes (with most
woman being naturally immunised), and donor protocols and recruitment strategies changed
over time. These facts may have induced or obscured associations between observed
outcomes.
We found no effect of gender on the fitted individual parameters, but we did find age to be
associated with the individual decline rate. Such an effect of age on antibody production,
including menopause induced for woman, and senescence effects, has been reported for differ-
ent antigens [9,10, 11]. Although our model might potentially be improved by incorporating
age, a changing decline rate would be challenging to implement. In addition, the impact of
such an extension is expected to be limited, as the observed age effect is only small when com-
pared to the overall intra-individual variation.
Differential drop-out of individuals does not lead to bias for factors modelled as random
effects at donor level. However, it is likely that donors with low anti-RhD titers stopped donat-
ing more frequently before the start of the data inclusion period (1998). Also, woman immu-
nised by pregnancy showing high anti-RhD titers are more likely to have been identified and
recruited. Therefore, the donor population analysed is likely characterised by relatively high
titers and is not expected to reflect the general Dutch population if immunised.
Much of the titer increase is already achieved at 14 days from boostering (the minimum
time between donations). Ideally, in order to obtain a better estimate for the timing of booster-
ing effect, in directed research multiple titer measurements would follow more closely upon
boostering. Further research of importance for boostering strategies would address the burden
of boostering as experienced by donors, and how this relates to the boostering frequency and
titer levels.
Our model validation shows that the model is relatively insensitive to outliers. Hence for
the prediction of future titers, for new donors only their two individual model parameters
need to be determined. However, defining what data is needed for a sufficiently accurate pre-
diction is complicated, as the precision in the decline rate depends on unboostered follow-up
time whereas the precision in boostering effect depends on the number of boosters and the
range of titers at boostering. Further research is required in order to adequately address this
problem.
Despite careful checking and excluding years of lower data quality, some documentation
errors or missing booster events likely remain in the data set, which may explain some of the
bad individual fits.
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A relatively large error was apparent in the titer measurements, especially when translated
to absolute scale on which the antibody yield ultimately depends. We expect that predictions
might be improved substantially if more accurate titer measurements would be available. The
fit distributions of the individual parameters would be narrower; fewer donors would be fit
with a spurious positive natural titer change. Enhanced prediction power given different mea-
surement scenarios could be assessed by simulations.
Model utility may also be improved if one could link the individual decline rate and sensi-
tivity to boostering to biological donor characteristics [12, 13]. If such associations could be
established, one could predict individual (new) donor responses on basis of for example donor
allotyping.
If certain biological factors would have a great impact on anti-RhD titer, we would expect
to see different groups of donors, rather than a continuum in the individual characteristics
[14]. However, we did not find any evidence for such sub-groups of donors. For example, we
observe a continuum in the mean titer over the donation career of donors (excluding their
first donation year) (results not shown). We expect however that individuals not responding
or hardly responding to boostering may form a sub-group of the population. A few of these in
the data-set strongly inflated the fitted variance in the decline rate (see S4 Fig). However, since
it was not recorded who were newly immunised, this data-set is not suitable for quantifying a
proportion of “non-responders” in the Dutch donor population.
Despite the fact that anti-RhD donors are an exceptionally motivated group of altruists,
burdening them by booster events should be avoided as much as possible. Current protocol
calls for boostering of donors when their titer declines by a factor of four (log2 2) below their
plateau value, or when their titer declines to below log2 9, but in principle not with a frequency
greater than once per year. Especially in light of the large measurement error obscuring actual
decline in titer, and the fact that apparent titer plateau is determined by past boostering fre-
quency, this protocol is not straightforward to follow. Measurement error may lead to delays
in boostering or unnecessary booster events. The latter could be the reason why we did not
observe any increase in titer after many of the given boosters (see Fig 3).
The model derived in this paper can be used to predict change in anti-RhD titers in donors
over time. This can be used to derive an enhanced immunization policy in which boostering is
adjusted to the anticipated anti-RhD decline, the effectiveness of boostering and the anti-RhD
titer required.
Supporting information
S1 Dataset. Subsequent donor titers at time of donation and indication of boostering of all
755 donors in our study.
(CSV)
S1 Fig. Change in anti-RhD titer after boostering. Same data are presented as in Fig 2 in the
main text, with additionally the measurements200 days from boostering (excluding from
view one log2 titer change measurement at -10).
(JPG)
S2 Fig. Peak in anti-RhD titer gain after boostering. Same data are presented as in Fig 3 in
the main text; here the titer change is plotted on an absolute scale.
(JPG)
S3 Fig. Relationship between the individually fitted titer decline parameter Di and an indi-
vidual’s age at first donation in the data-set. Pearson’s correlation coefficient is −0.119
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(p = 0.001).
(JPG)
S4 Fig. Histograms of the individual model parameter values for the 755 donors, overlaid
with the normal distributions of the random effects model fit. Top: the log decline rate per
day Di. Bottom: the saturation speed in decline of boostering effect with log2 starting titer, Li
(excluding the 165 donors who were never boostered).
(JPG)
S5 Fig. Model fit per donor to observed titers and boostering events over time.
(PDF)
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